Cis‐platinum therapy of previously treated head and neck cancer: The Southwest Oncology Group's two‐dose‐per‐month outpatient regimen

Frank J. Panettiere, Daniel Lehane, William S. Fletcher, Ronald Stephens, J. Dean McCracken, Saul Rivkin

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

The Southwest Oncology Group tested an outpatient Cis-platinum regimen in patients with carcinoma of the head and neck. Courses which consisted to two doses, a week apart, were schedules to be given at 4-week intervals. Eighty-nine poor risk head and neck cancer patients, who had received extensive prior therapy with surgery, radiation, and/or multiple drugs were studied. Sixteen (18% of all entered and 25% of the 65 fully evaluable) had objective tumor regression. The median duration of response was 136 days. Toxicity was moderate. Myelosuppression was minimal with only 3% of patients exhibiting leukocyte nadirs below 2,000 and less than 2% experiencing platelet counts below 50,000. Significant, but reversible, impairment of renal function occurred in 8% of patients. Individual susceptibility to such renal toxicity appears to have been predictable. This simple outpatient program with its effectiveness and minimal toxicity in poor risk patients deserves further utilization.

Original languageEnglish (US)
Pages (from-to)221-225
Number of pages5
JournalMedical and Pediatric Oncology
Volume8
Issue number3
DOIs
StatePublished - 1980

Keywords

  • cis‐platinum
  • head and neck cancer
  • toxicity
  • two dose

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Cis‐platinum therapy of previously treated head and neck cancer: The Southwest Oncology Group's two‐dose‐per‐month outpatient regimen'. Together they form a unique fingerprint.

Cite this